GLP-1s and PCOS: what the evidence actually supports

What's this video probably claiming?

Based on the caption and hashtags, this video is almost certainly a personal experience post from someone with PCOS sharing what has or hasn't worked for weight loss, with GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) likely featured prominently. The #insulinresistance tag is a signal that the creator is probably connecting insulin dysfunction to PCOS weight struggles, which is a legitimate framing but one that gets oversimplified fast on TikTok. The comment-soliciting format means viewers are also pooling anecdotes, which creates a feedback loop where the loudest success stories dominate. Expect claims that GLP-1s are a fix for PCOS weight gain, possibly alongside assertions that insulin resistance is the root cause of PCOS in all cases, and that semaglutide addresses that root cause directly. Some of this is grounded in real biology. Some of it is extrapolated far beyond what the current data actually supports for this specific population.

What does the science actually show?

The honest answer is: promising but preliminary. A 2023 randomized controlled trial by Elkind-Hirsch et al. published in the Journal of Clinical Endocrinology and Metabolism looked at liraglutide 1.8mg in women with PCOS and found meaningful improvements in weight, androgen levels, and menstrual regularity compared to placebo. That's real. But liraglutide is not semaglutide, and effect sizes varied considerably based on whether participants had confirmed insulin resistance. A 2022 meta-analysis by Liu et al. in Frontiers in Endocrinology pooled 12 trials of GLP-1 agonists in PCOS patients and found average weight reductions of around 4-6kg over 12-24 weeks, with improvements in HOMA-IR scores, but noted that most trials were small, short, and not powered to assess fertility or long-term hormonal outcomes. Semaglutide at the 2.4mg weekly dose used in STEP trials has not been studied in a dedicated PCOS-only RCT as of this writing. The biology is logical. The specific clinical data is thinner than the TikTok enthusiasm suggests.

Where does the social media noise diverge from clinical reality?

Several places. First, the insulin resistance narrative gets applied universally to PCOS when in reality roughly 70-80% of women with PCOS show some degree of insulin resistance, but not all. Treating it as a universal explanation flattens a condition with multiple phenotypes. Second, anecdotal weight loss on GLP-1s gets attributed specifically to PCOS management, when the mechanism is largely appetite suppression and gastric slowing that works similarly in people without PCOS. Third, comment sections on these videos routinely include claims about restored periods or improved fertility after starting GLP-1s. These outcomes have been observed in case reports and small studies, but they are not consistent or predictable enough to present as expected outcomes. The Joham et al. 2022 review in Lancet Diabetes and Endocrinology specifically flags that reproductive outcomes in PCOS require individualized clinical assessment, not population-level assumptions from weight loss data alone. The gap between plausible mechanism and confirmed clinical outcome is real and matters.

What should you actually know?

If you have PCOS and are considering a GLP-1 agonist, the conversation should start with a clinician who has actually reviewed your labs, not a comment section. Insulin resistance status, BMI, androgenic profile, and reproductive goals all shape whether and how a GLP-1 might be appropriate for you. Semaglutide and tirzepatide are not FDA-approved specifically for PCOS; any use in that context is off-label. That doesn't make it inappropriate, but it means the prescribing decision requires more clinical judgment, not less. Metformin remains the most evidence-supported insulin sensitizer for PCOS with a decades-long safety record, and some guidelines still list it as first-line before GLP-1s. Lifestyle interventions including dietary changes showed weight loss of 5-10% in multiple trials, which is enough to restore ovulation in some women. GLP-1s may offer real benefit for a subset of PCOS patients. Framing them as the answer for every PCOS body is getting ahead of the evidence considerably.